Sort   by:  
 Page size 
UnknownEfficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
Not available
S-EPMC4872317 | biostudies-literature
MetabolomicsMetabolomics guides rational development of a simplified cell culture medium for drug screening against Trypanosoma brucei
In vitro culture methods underpin many experimental approaches to biology and drug discovery. The modification of established cell culture methods to be more biologically relevant, or to optimise growth, is traditionally a laborious task. Emerging metabolomics technology enables rapid evaluation of ...
2015-05-14 | MTBLS49 | MetaboLights
UnknownField-induced magnetic instability within a superconducting condensate.
Not available
S-EPMC5438216 | biostudies-literature
UnknownLong-Range Proton Channels Constructed via Hierarchical Peptide Self-Assembly.
Not available
S-EPMC11636193 | biostudies-literature
UnknownLoss of ABCA8B decreases myelination by reducing oligodendrocyte precursor cells in mice.
Not available
S-EPMC8953628 | biostudies-literature
UnknownSkin microbiome-biophysical association: a first integrative approach to classifying Korean skin types and aging groups.
Not available
S-EPMC12277360 | biostudies-literature
Proteomics,MultiomicsMining the Human Urine Proteome for Monitoring Renal Transplant Injury
a) 8-plex iTRAQ-based quantitative proteomics analysis of the urine proteome comparing 4 different clinical conditions; b) Label-free LC-MS analyses of individual urine samples from different clinical conditions
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2015-08-18 | MSV000079262 | MassIVE
UnknownMutation in the Monocarboxylate Transporter 12 Gene Affects Guanidinoacetate Excretion but Does Not Cause Glucosuria.
Not available
S-EPMC4849831 | biostudies-literature
UnknownPharmaceuticals and personal care products in the environment: what are the big questions?
Not available
S-EPMC3440110 | biostudies-literature
UnknownConsensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.
Not available
S-EPMC3319201 | biostudies-literature
Sort   by:  
 Page size